Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
A Complex Case of Neuro-Behçet's Disease in a Patient Previously Diagnosed with multiple Sclerosis: A Case Report.
Motor skill learning requires active central myelination.
Potassium channel KIR4.1 as an immune target in multiple sclerosis.
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.
Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis.
Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse Remitting Multiple Sclerosis
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate.
Pattern of remyelination in the CNS.
[Assessment of the pain patients with the multiple sclerosis after applying the physiotherapy treatment].
UCSF Seminar: "The needle in the haystack: Searching for target antigens of the adaptive immune response in MS."
International Joint Israel-Greek-Italian Neuroimmunological meeting
Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study.
Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.
Vision Disturbances in Multiple Sclerosis.
Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65.
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Advanced Structural and Functional Brain MRI in Multiple Sclerosis.
Headwaters of the zebrafish -- emergence of a new model vertebrate.
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus - induced demyelinating disease by modifying Nrf2-Keap1 pathway.
Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis.
Pages
« first
‹ previous
…
81
82
83
84
85
86
87
88
89
…
next ›
last »